Presentasjon lastes. Vennligst vent

Presentasjon lastes. Vennligst vent

1 TEKNA Oslo Plaza 16.10.09 PhD utdanningen Umodne arbeids- & kunnskapsmarked Bioteknologi Berit Johansen, professor og gründer Avexxin AS/NTNU Berit Johansen,

Liknende presentasjoner


Presentasjon om: "1 TEKNA Oslo Plaza 16.10.09 PhD utdanningen Umodne arbeids- & kunnskapsmarked Bioteknologi Berit Johansen, professor og gründer Avexxin AS/NTNU Berit Johansen,"— Utskrift av presentasjonen:

1 1 TEKNA Oslo Plaza PhD utdanningen Umodne arbeids- & kunnskapsmarked Bioteknologi Berit Johansen, professor og gründer Avexxin AS/NTNU Berit Johansen, IBI mars 2006

2 2 OECDs definisjon av Bioteknologi: "Anvendelse av naturvitenskap og teknologi på levende organismer og på deler, produkter og modeller av disse, slik at levende eller ikke- levende materiale endres for å frembringe kunnskap, varer og tjenester."

3 3 Bioteknologisk industri– en ung industri ? Verdens første biotekfirma: Genentech (1976) San Fransisco, US, Swanson og Boyer. Biogen Inc (1978) Geneve, SCH, W. Gilbert (Nobelprisen i 1980)

4 4 Det Globale Biotek Racet – økonomisk betydelig? “Our biotechnology industry is the strongest in the world – and we need to keep it that way” President George W. Bush, Bio 2003 in Washington DC ”Public research across EU to the value of € 70 billion is unexploited” Former EU Director of Research Bruno Hansen, MVA BioConference 2002 US biotech turnover is expected to increase to an almost 20% GDP contribution in year 2010

5 5 European biotechnology industry younger and lags the US on several parameters * No. of drug candidates in clinical development Biotechnology Outlook , bnUSD 13,9 bnUSD 6,1 bnUSD 225 bnUSD No. biotech companies Employees Product Pipeline* VC investments Revenues R&D Expenses Net Loss Market Cap USA (2001): , ,1 bnUSD 45 bnUSD 6,6 bnUSD 1,3 bnUSD Europe (2001): 1,2 bnUSD5 bnUSD

6 6 Germany had the most companies…

7 7 doubling in government spending on science from : £ 3 bn (2005) •at present largest biotech country in Europe •UK Biotech companies: 485 (2004) •Biotech employment: •UK Biotech products in clinical testing: 40% of EU drug candidates •UK Biotech secure more than 40% of European VC Lord Sainsbury, UK minister of Science and Innovation, at BioTech Forum Science conf. oct.o4, Copenhagen:

8 8 Major Bio-clusters world wide

9 9 Boston •280 biotechnology companies •Biotech and drug companies employ more than 30,000 people

10 10 Cambridge and east of England •185 biotech companies •20% of the world's Nobel Prize winners in medicine and chemistry

11 11 Bay Area, Northern California •More than 600 bioscience companies and 820 life science companies •24% of the $300 billion U.S. biotech market cap is in the Bay Area; 68% is in the state of California (2004 figures) •30% of total U.S. venture capital funding went to companies located in the Bay Area (2004 figure) •Venture capital firms invested $797 million in local biopharmaceutical companies (2003 figure) •5 world-renowned research universities

12 12 San Diego •21,000 employed in life science industry •178 Life Science companies •UCSD 10 Nobel laureates •NIH awarded research funds 2003: 316 M USD •12 Biotech Research Institutes * Data from analysis by Milken institute

13 13 Stockholm-Uppsala •230 companies with 20,000 employees •5 universities •3,750 scientists and 6,160 PhD students •8 Nobel Laureates within Medicine and Chemistry

14 14 Medicon Valley •Population 3 million •14 universities - all part of the Öresund University •150,000 university students •5,000 life science researchers •26 hospitals, of which 11 are university hospitals •41,000 people employed in life science •More than 500 companies within the biotech, medtech and human life science fields - more than 200 companies work within R&D •A strong infrastructure within the health care sector •Excellence in some of the most commercially attractive disease areas •Copenhagen Airport - Scandinavia's main airport - has approx. 20 million national and international passengers annually

15 15 University ranking 2005 From top 100 World University ranking. From: Institute of Higher Education, Shanghai Jiao Tong University, •Region ranked by top University –Boston: Harvard:1, MIT:5, Boston:80, Tuffts:100 –Cambridge UK :2 –Bay Area: Stanford:3, Berkley:4, UCSF:18, Davis: 41 –New York: Columbia:7, NY U:29, Rockefeller:30, –Oxford:10 –San Diego: UCSD:13 –London: Imperial Coll:23, Univ Coll:26, Kings Coll:80 –Res. Triangle: Duke: 32, Chapel Hill:55 –Stockholm/Uppsala: Karolinska: 45, Uppsala:60, Stockholm:93 –Paris: U.Paris-06:46, U.Paris-11:61, ENSP:93 –Medicon Valley: Copenhagen:57, Lund:99 –BioValley; Basel:87, Freiburg:90, Strasbourg:92

16 16

17 17 Norwegian Biotech Industry Norwegian biotech industry sorted according to subsector. A total of 110 companies employ close to 5000 people and generate total revenue of NOK 12 billion (2004).

18 18 Norsk Biotek-industri fordelt etter universitets-tilhørighet (2005)

19 19

20 20 PhD–utdanning i Bioteknologi Hittil ved norske universiteter: •Teknologi- prosessbasert, f.eks fermentering •Molekylærbiologi-baserte

21 21 PhD–utdanning i Bioteknologi Utfordringer: •Behovet for forsker-arbeidskraft i bioteknologiindustrien er skiftet fra det teknologibaserte til det vitenskapsbaserte •Dagens “big pharma” har ikke lengre egne legemiddelkandidater, og er avhengige av biotekfirma for å fylle sine “pipelines” •En nisje skapes derved for vitenskapsbaserte bioteknologifirma

22 22 PhD–utdanning i Bioteknologi Morgendagens utdanning: •Vitenskapsbasert, høykvalitets forskning etter internasjonale suksesskriterier •Tverrfaglig (celle/molekylærbiologi, immunologi, biokjemi, FUGE, statistisk/datavitenskapelig kunnskapsoppdaging) •Bevissthet rundt patentering/kommersialiserings-mekanismer

23 23 Takk for oppmerksomheten!


Laste ned ppt "1 TEKNA Oslo Plaza 16.10.09 PhD utdanningen Umodne arbeids- & kunnskapsmarked Bioteknologi Berit Johansen, professor og gründer Avexxin AS/NTNU Berit Johansen,"

Liknende presentasjoner


Annonser fra Google